Drug Profile


Alternative Names: HM 71224; LY 3337641

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Hanmi Pharmaceutical
  • Developer Eli Lilly; Hanmi Pharmaceutical
  • Class Antirheumatics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 15 Mar 2017 Eli Lilly initiates enrolment in a phase I trial in Healthy volunteers in USA (NCT03083561)
  • 01 Nov 2016 Eli Lilly completes a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02914379)
  • 22 Sep 2016 Eli Lilly plans a phase I pharmacokinetics trial in Healthy volunteers in USA (PO) (NCT02914379)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top